Related Experiment Video
Updated: Apr 5, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
Renin-aldosterone testing: The essentials
Eunice K T Phillips1, Abilash Sathyanarayanan2
1Oxford University School of Medicine & Biomedical Sciences, University of Oxford, Oxford, UK.
Insights
Primary Aldosteronism (PA), a common cause of hypertension, is underdiagnosed. Early screening and treatment significantly reduce cardiovascular and renal risks in affected patients.
Area of Science:
- Endocrinology
- Cardiology
- Nephrology
Background:
- Primary Aldosteronism (PA) is an underdiagnosed cause of secondary hypertension, affecting approximately 9.4% of hypertensive adults.
- PA patients have significantly higher risks of adverse cardiovascular and renal outcomes.
- Early diagnosis and treatment can substantially mitigate these risks.
Purpose of the Study:
- To provide a practical, evidence-based approach for PA screening in generalist settings.
- To focus on contemporary test interpretation and common pitfalls in PA diagnosis.
- To encourage improved screening rates for greater global health benefit.
Main Methods:
- Screening involves a simple blood test measuring plasma aldosterone and renin levels.
- The diagnostic hallmark is renin-independent aldosterone production, indicated by suppressed renin.
- Initial testing is recommended on the current antihypertensive regimen, with medication withdrawal if results are inconclusive.
Main Results:
- Renin-independent aldosterone production is the key diagnostic indicator.
- Most antihypertensive medications can interfere with initial test results.
- Specialist referral is indicated for suspected PA or complex cases, such as those with chronic kidney disease.
Conclusions:
- Improving PA screening offers a significant opportunity to reduce hypertension-related morbidity and mortality globally.
- Practical screening guidelines are essential for generalist settings to address the underdiagnosis of PA.
- Timely diagnosis and targeted treatment of PA are crucial for mitigating adverse patient outcomes.
Abstract:
Primary aldosteronism (PA) is a common yet significantly underdiagnosed cause of secondary hypertension, estimated to affect around 9.4% of hypertensive adults. This is critical because patients with PA face markedly higher rates of adverse cardiovascular and renal outcomes, risks substantially mitigated by targeted treatment (surgery or medical therapy). Despite this, screening rates remain critically low. This article provides a practical, evidence-based approach to PA screening specifically for generalist settings, focusing on contemporary test interpretation and mitigating common pitfalls. Screening involves a simple blood test for plasma aldosterone and renin. The diagnostic hallmark is renin-independent aldosterone production, demonstrated by suppressed renin. While most antihypertensives interfere, the initial approach is to test patients on their current regimen. If results are inconclusive, medication withdrawal is warranted. Specialist referral is necessary when results are suggestive of PA, or in complex cases like chronic kidney disease. Improving PA screening offers a significant opportunity for substantial global benefit in reducing hypertension-related morbidity and mortality.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Hormonal Regulation
Serum Studies: Renal Function Tests
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Hypertension II: Pathophysiology
Regulation of Sodium and Potassium
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily...

